HELWAN UNIVERSITY
🇪🇬Egypt
- Country
- 🇪🇬Egypt
- Ownership
- Private
- Established
- 1975-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.helwan.edu.eg
Clinical Trials
56
Active:2
Completed:42
Trial Phases
4 Phases
Phase 2:4
Phase 3:5
Phase 4:7
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (41 trials with phase data)• Click on a phase to view related trials
Not Applicable
25 (61.0%)Phase 4
7 (17.1%)Phase 3
5 (12.2%)Phase 2
4 (9.8%)Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Not Applicable
Completed
- Conditions
- Anti-CD30BrentuximabDoxorubicinVinblastineDacarbazineFrontlineAdvanced Classical Hodgkin Lymphoma
- Interventions
- Drug: Brentuximab Vedotin + Doxorubicin, Vinblastine, and DacarbazineDrug: Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Helwan University
- Target Recruit Count
- 60
- Registration Number
- NCT07171827
- Locations
- 🇪🇬
Helwan University, Helwan, Egypt
A Double-Blind, Placebo-Controlled Study of Fermented Deglycyrrhizinated Licorice Extract
Not Applicable
Completed
- Conditions
- Diabetic Polyneuropathy
- Interventions
- Drug: Fermented Deglycyrrhizinated LicoriceDietary Supplement: Non-fermented Deglycyrrhizinated Licorice
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Helwan University
- Target Recruit Count
- 83
- Registration Number
- NCT07148804
- Locations
- 🇪🇬
Al-Azhar University, Cairo, Nasr City, Egypt
Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy
Completed
- Conditions
- Gonadotropin Releasing Hormone AgonistsOvarian FunctionPremenopausalBreast CancerChemotherapy
- Interventions
- Drug: Gonadotropin-releasing hormone agonistDrug: Chemotherapy
- First Posted Date
- 2025-08-17
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Helwan University
- Target Recruit Count
- 100
- Registration Number
- NCT07127315
- Locations
- 🇪🇬
Helwan University, Helwan, Egypt
FDGL Dose-Finding Study for Diabetic Neuropathy
Not Applicable
Completed
- Conditions
- Diabetic Neuropathy
- Interventions
- Drug: Fermented Deglycyrrhizinated Licorice (FDGL)
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Helwan University
- Target Recruit Count
- 485
- Registration Number
- NCT07117942
- Locations
- 🇪🇬
Al-Azhar University, Cairo, Nasr City, Egypt
Nurse-Led Implementation of the ABCDEF Bundle
Not Applicable
Completed
- Conditions
- Delirium in the Intensive Care Unit
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Helwan University
- Target Recruit Count
- 140
- Registration Number
- NCT07054268
- Locations
- 🇪🇬
Helwan University, Helwan, Cairo, Egypt
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
No news found